Additionally, the 36-month beta value for AIM is -0.34. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for AIM is 57.62M and currently, short sellers hold a 0.85% ratio of that float. The average trading volume of AIM on November 15, 2024 was 301.14K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
AIM) stock’s latest price update
AIM ImmunoTech Inc (AMEX: AIM)’s stock price has gone decline by -5.07 in comparison to its previous close of 0.25, however, the company has experienced a -1.68% decrease in its stock price over the last five trading days. seekingalpha.com reported 2024-11-15 that AIM ImmunoTech Inc. (NYSE:AIM ) Q3 2024 Earnings Call Transcript November 15, 2024 8:30 AM ET Company Participants Thomas Equels – CEO Christopher McAleer – Scientific Officer Conference Call Participants Ed Woo – Ascendiant Capital Markets Operator Hello, and welcome to the AIM ImmunoTech Third Quarter 2024 Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.
AIM’s Market Performance
AIM ImmunoTech Inc (AIM) has seen a -1.68% fall in stock performance for the week, with a -7.37% decline in the past month and a -22.61% plunge in the past quarter. The volatility ratio for the week is 10.35%, and the volatility levels for the past 30 days are at 8.92% for AIM. The simple moving average for the last 20 days is -5.67% for AIM’s stock, with a simple moving average of -33.82% for the last 200 days.
AIM Trading at -9.82% from the 50-Day Moving Average
After a stumble in the market that brought AIM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.31% of loss for the given period.
Volatility was left at 8.92%, however, over the last 30 days, the volatility rate increased by 10.35%, as shares sank -4.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -26.89% lower at present.
During the last 5 trading sessions, AIM fell by -1.72%, which changed the moving average for the period of 200-days by -44.87% in comparison to the 20-day moving average, which settled at $0.2543. In addition, AIM ImmunoTech Inc saw -45.46% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AIM starting from Equels Thomas K, who purchase 5,000 shares at the price of $0.30 back on Sep 16 ’24. After this action, Equels Thomas K now owns 1,493,042 shares of AIM ImmunoTech Inc, valued at $1,515 using the latest closing price.
Equels Thomas K, the CEO & President of AIM ImmunoTech Inc, purchase 20,000 shares at $0.31 during a trade that took place back on Sep 13 ’24, which means that Equels Thomas K is holding 1,488,042 shares at $6,160 based on the most recent closing price.
Stock Fundamentals for AIM
Current profitability levels for the company are sitting at:
- -146.84 for the present operating margin
- 0.24 for the gross margin
The net margin for AIM ImmunoTech Inc stands at -125.94. The total capital return value is set at -8.0. Equity return is now at value -154.79, with -113.70 for asset returns.
Based on AIM ImmunoTech Inc (AIM), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at -34.76. The debt to equity ratio resting at 0.23. The interest coverage ratio of the stock is -40.85.
Currently, EBITDA for the company is -31.68 million with net debt to EBITDA at 0.01. When we switch over and look at the enterprise to sales, we see a ratio of 78.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.17.
Conclusion
In conclusion, AIM ImmunoTech Inc (AIM) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
